孙瑜晨. 专利反向支付协议反垄断规制探论:美国的经验及启示[J]. 科技进步与对策, 2019, 36(24): 128-135.
Sun Yuchen. Antitrust Regulation toward Patent Reverse Payment Settlement:Experience in the United States and Its Implications. SCIENCE & TECHNOLOGY PROGRESS AND POLICY, 2019, 36(24): 128-135.
[1] LAURA J ROBINSON.Analysis of recent proposals to reconfigure hatch-waxman[J].Journal of Intellectual Property Law,2003,11(1):7-48.
[2] HENRY N BUTLER,JEFFREY PAUL JAROSCH.Policy reversal on reverse payments:why courts should not follow the new DOJ position on reverse-payment settlements of pharmaceutical patent litigation[J].Iowa Law Review,2010,96(1):108.
[3] MICHAEL A CARRIER.Solving the drug settlement problem:the legislative approach[J].Rutgers Law Journal,2009,41(1&2):97-98.
[4] CORY J INGLE.Reverse payment settlements:a patent approach to defending the argument for illegality[J].I/S:A Journal of Law and Policy,2011,7(2):534.
[5] ZHENGHUI WANG.Reanalyzing reverse payment settlements:a solution to the patentee's dilemma[J].Cornell Law Review,2014,99(5):1239.
[6] MICHAEL A CARRIER.Why the cope of the patent test cannot solve the drug patent settlement problem[J].Stanford Technology Law Review,2012,16(1):2-6.
[7] KIMBERLY A MOORE.Judges,juries,patent cases:an empirical peek inside the black box[J].Michigan Law Review,2000,96(2):385.
[8] CARL SHAPIRO.Antitrust limits to patent settlements[J].RAND Journal of Economics,2003,34:391-395.
[9] HERBERT HOVENKAMP,MARK JANIS,MARK A LEMLEY.Anticompetitive settlement of intellectual property disputes[J].Minnesota Law Review,2003,87(6):1735.
[10] DAVID W OPDERBECK.Rational antitrust policy and reverse payment settlements in hatch-waxman patent litigation[J].The Georgetown Law Journal,2010,98(5):1329-1333.
[11] THOMAS F COTTER.FTC v Actavis,inc:when is the rule of reason not the rule of reason[J].MINN.J.L.SCL & TECH,2014(15):41-49.
[12] [美]克里斯蒂娜·博翰楠,赫伯特·霍温坎普.创造无羁限:促进创新中的自由与竞争[M].兰磊,译.北京:法律出版社,2016:106.
[13] 严仁群.“消失中的审判”?——重新认识美国的诉讼和解与诉讼调解[J].现代法学,2016(5):165.
[14] 白光清.药品专利之战[M].北京:知识产权出版社,2018:21.
[15] 苏华,韩伟.药业反向支付协议反垄断规制的最新发展——兼评Actavis案及Lundbeck案[J].工商行政管理,2013(16):38-41.
[16] MICHAEL CLANCY,DAMIEN GERADIN,ANDREW LAZEROW.Reverse-payment patent settlements in the pharmaceutical industry:an analysis of us antitrust law and eu competition law[J].The Antitrust Bulletin,2014,59(1):163-164.
[17] MICHAEL A CARRIER.Drug patent settlements around the world[J].The Antitrust Bulletin,2017,62(4):770-785.
[18] SEIKO F OKADA.In re k-dur antitrust litigation:pharmaceutical reverse payment settlements go beyond the scope of the patent[J].North Carolina Journal of Law & Technology,2012,14(1):307.
[19] [美]赫伯特·霍温坎普.反竞争性专利和解协议与最高法院对阿特维斯案的判决[J].孙瑜晨,译.竞争政策研究,2019(2):56-73.
[20] 陶冠东.反向支付的反垄断法适用[J].竞争政策研究,2017(3):86.
[21] 叶卫平.反垄断法分析模式的中国选择[J].中国社会科学,2017(3):96.
[22] MICHAEL A CARRIER.The real rule of reason:bridging the disconnect[J].Brigham Young University Law Review,2006(1999):1265.
[23] JOSHUA P DAVIS.Applying litigation economics to patent settlements:why reverse payments should be per se illegal[J].Rutgers Law Journal,2009,41(1&2):258-261.
[24] 时建中,郝俊淇.原则性禁止转售价格维持的立法正确性及其实施改进[J].政治与法律,2017(11):20-33.